TRVI Earnings & Financial Statements
Trevi Therapeutics, Inc.
$12.06
-$0.23(-1.87%)
40
Overall
45
Value
36
Tech
39
Quality
Market Cap
$1.72B
Volume
3.04M
52W Range
$9.28 - $20.22
Target Price
$28.69
TRVI earnings and financial statements: Trevi Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TRVI Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$49.33M | -$51.52M | -$33.92M | -$29.91M | -$32.48M |
| EBITDA | -$42.24M | -$47.33M | -$28.42M | -$27.98M | -$32.71M |
| Net income | -$42.76M | -$47.91M | -$29.07M | -$29.15M | -$33.94M |
| EPS (diluted) | $-0.32 | $-0.47 | $-0.29 | $-0.45 | $-1.49 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $193.44M | $110.90M | $89.40M | $123.02M | $38.48M |
| Total liabilities | $10.20M | $11.26M | $6.86M | $15.56M | $21.40M |
| Shareholders’ equity | $183.24M | $99.64M | $82.55M | $107.46M | $17.07M |
| Cash and equivalents | $18.91M | $34.10M | $32.40M | $12.59M | $36.80M |
| Long-term debt | $446.0K | $747.0K | $1.03M | $2.15M | $8.68M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$42.09M | -$38.26M | -$31.71M | -$28.18M | -$28.95M |
| Capital expenditure | -$12.0K | -$35.0K | -$137.0K | -$159.0K | - |
| Free cash flow | -$42.10M | -$38.29M | -$31.85M | -$28.33M | -$28.95M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TRVI | $12.06 | -1.9% | 3.04M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Trevi Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW